AnalyzeDirect

Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy

Keqiang Zhang et al. Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy Theranostics. Publication Date September 2, 2026 How Analyze was Used “To evaluate the impact of Usp22-KO on tumor growth in vivo, changes in tumor volume were measured over 4 weeks through serial CT scans. Serial lung images…